HLA-C and neoplasm: Even so, a composite predictor is needed; it should include critical variables such as the ability of the patient’s major histocompatibility complex (MHC) to present specific neo-antigens, the host’s T cell receptor recognition repertoire, the specific checkpoints utilized by the tumor to shield itself from the immune system (e.g. CTLA- 4, LAG- 3, etc.), and the immunogenicity of the neo-antigens produced by the mutanome [39, 14, 10].